Tectonic Therapeutic, Inc. (NASDAQ: TECX) is a clinical-stage biotechnology company headquartered in Watertown, Massachusetts, focused on therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs). The TECX news stream highlights how the company advances its GPCR-targeted biologic pipeline, particularly in pulmonary hypertension and hereditary bleeding disorders.
Company press releases frequently cover clinical trial milestones for TX45, a long-acting Fc-relaxin fusion protein that activates the RXFP1 receptor. Updates include interim and complete Phase 1b data in Group 2 pulmonary hypertension in heart failure with preserved and reduced ejection fraction (PH-HFpEF and PH-HFrEF), the ongoing APEX Phase 2 trial in PH-HFpEF, and plans for a Phase 2 study in Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). Tectonic also reports on the planned clinical development of TX2100, a GPCR-targeting biotherapeutic for Hereditary Hemorrhagic Telangiectasia (HHT).
Investors following TECX news will also see financial results and operating updates released with each quarter, as well as announcements about private placements, index inclusion such as entry into the Russell 3000® Index, and participation in healthcare and investor conferences. These items provide context on Tectonic’s cash position, research and development spending, and engagement with the investment community.
This news page aggregates Tectonic’s press releases and related disclosures so readers can review clinical data readouts, trial initiation plans, financial updates, and conference appearances in one place. For anyone tracking GPCR-focused biologic development and pulmonary hypertension programs, the TECX news feed offers a focused view of the company’s reported progress and key events over time.
Tectonic Therapeutic (NASDAQ: TECX) reported Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs. The company's TX45 Phase 1b trial showed promising interim results with a 17.9% reduction in Pulmonary Capillary Wedge Pressure in PH-HFpEF patients and over 30% reduction in Pulmonary Vascular Resistance in CpcPH patients.
Financial highlights include $141.2 million in cash and cash equivalents as of December 31, 2024, plus $185.0 million from a February 2025 private placement, extending cash runway into Q4'28. Q4 2024 saw increased R&D expenses of $9.2 million (vs $7.1M in Q4 2023) and net loss of $12.4 million (vs $7.9M in Q4 2023).
Key upcoming milestones include Phase 1b Part B results expected in 2H'25, APEX Phase 2 trial results in 2026, and TX2100 Phase 1 initiation for HHT treatment in Q4'25 or Q1'26.
Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company specializing in therapeutic proteins and antibodies for G-protein coupled receptors (GPCRs), has announced its participation in two investor conferences scheduled for March 2025.
The company will provide live webcasts of both events, accessible through the 'Events & Presentations' section of their website at www.tectonictx.com. Recordings will remain available for approximately 90 days after the conferences conclude.
The management team will conduct one-on-one meetings with investors during both conferences. Interested parties are advised to contact their TD Cowen and/or Leerink representatives to arrange meetings.
Tectonic Therapeutic (NASDAQ: TECX) has secured a private investment in public equity (PIPE) financing of $185.0 million through the issuance of 3,689,465 shares of common stock. The shares will be priced at $50.00 per share for fund investors and $54.14 per share for company officers and directors.
The PIPE financing attracted both new and existing investors, including notable participants such as Adage Capital Partners LP, Ally Bridge Group, Deep Track Capital, and several other prominent investment firms. The proceeds will be used to fund the clinical development of TX45 and TX2100, discovery platform development, working capital, and general corporate purposes.
The transaction is expected to close on February 5, 2025, subject to customary closing conditions. TD Cowen, Leerink Partners, Piper Sandler, and Wells Fargo Securities served as placement agents for the PIPE.
Tectonic Therapeutic (NASDAQ: TECX) announced positive interim data from its Phase 1b trial of TX45, showing significant improvements in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF). The trial demonstrated a 17.9% reduction in Pulmonary Capillary Wedge Pressure in the total study population and over 30% reduction in Pulmonary Vascular Resistance in patients with more severe disease (CpcPH).
The interim analysis included 16 of 19 enrolled patients, with 9 having CpcPH. TX45 was well-tolerated with no serious adverse events. The drug showed improvement in both left ventricular function and pulmonary hemodynamics, demonstrating a unique therapeutic profile compared to other PAH drugs. The company's ongoing APEX Phase 2 trial is expected to deliver topline results in 2026.
Tectonic Therapeutic (NASDAQ: TECX) announces a virtual key opinion leader (KOL) event scheduled for December 12, 2024, from 4:00 PM to 6:00 PM ET. The event will feature experts Dr. John R. Teerlink from UC San Francisco and Dr. Raymond L. Benza from Icahn School of Medicine at Mount Sinai.
The discussion will focus on the unmet medical needs and current treatment landscape for Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (Group 2 PH-HFpEF). The event will highlight Tectonic's lead program, TX45, an Fc-relaxin fusion protein that activates the RXFP1 receptor. TX45 is currently being evaluated in both Phase 1b hemodynamic and Phase 2 clinical proof-of-concept studies for Group 2 PH-HFpEF treatment.
Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company specializing in G-protein coupled receptors (GPCRs), has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The event will take place in New York from December 3-5, 2024. Alise Reicin, MD, President and CEO, will deliver a presentation on Tuesday, December 3rd, 2024, at 12:30 PM ET.
The presentation will include one-on-one meetings and will be accessible via webcast. Interested parties can access the live webcast through the Investors section of Tectonic's website, where a replay will remain available for approximately 90 days after the conference.
Tectonic Therapeutic announced positive Phase 1a results for TX45, its long-acting Fc-relaxin fusion protein. The trial, involving 55 healthy volunteers, demonstrated favorable safety profile with no severe adverse events or anti-drug antibodies. TX45 showed a half-life of 14-20 days and approximately 50% subcutaneous bioavailability. The drug increased renal plasma flow across all doses, with mean cohort effects up to 42%. Based on these results, two doses (300mg Q2W and Q4W) were selected for the ongoing APEX Phase 2 trial in PH-HFpEF patients. Topline results are expected in late 1Q or early 2Q'2025 for Phase 1b, and in 2026 for Phase 2.
Tectonic Therapeutic (NASDAQ: TECX) reported Q3 2024 financial results and business updates. Patient enrollment in Phase 1b hemodynamic trial is ahead of schedule, with topline results expected in late Q1'2025 or early Q2'2025. The company dosed its first subject in the APEX Phase 2 trial for TX45 in October, with results expected in 2026. Cash position stands at $159.1 million, providing runway into mid-2027. Q3 net loss increased to $17.7 million from $10.1 million year-over-year. The company selected TX002100 as its development candidate for treating Hereditary Hemorrhagic Telangiectasia, with Phase 1 trials expected to begin in Q4'2025 or Q1'2026.
Tectonic Therapeutic (NASDAQ: TECX) announced favorable Phase 1a topline data for its lead asset TX45, a long-acting relaxin being developed for Group 2 PH-HFpEF treatment. The trial demonstrated TX45's safety, tolerability, and favorable PK/PD profile with no observed immunogenicity. Doses of 0.3, 1, and 3 mg/kg (IV) and 150, 300, and 600 mg (SC) were tested. Based on these results, Tectonic has selected doses for its global Phase 2 randomized clinical trial.
The company also reported progress in its Phase 1b single-dose hemodynamic proof-of-concept trial, which has escalated to the highest dose of TX45 (3 mg/kg). Topline results for this trial are expected in Q2 2025. Tectonic has initiated screening for the Phase 2 APEX clinical trial, with topline results anticipated in 2026.
Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company focused on G-protein coupled receptors (GPCRs), has announced its participation in two major investor conferences in September 2024. The company will present at the 2024 Wells Fargo Healthcare Conference in Boston on September 4, featuring a fireside chat with CEO Alise Reicin at 3:45 PM ET. Additionally, Tectonic will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 6, engaging in one-on-one investor meetings.
A live webcast of the Wells Fargo conference presentation will be available on Tectonic's website, with a replay accessible for approximately 90 days. These conferences provide Tectonic with opportunities to showcase its progress in developing therapeutic proteins and antibodies that modulate GPCR activity to potential investors and industry professionals.